Monday, February 12, 2007

Great news for Onyx and Liver Cancer Patients

Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer

Trial to be Stopped Early Based on Positive Outcome

WEST HAVEN, Conn., and EMERYVILLE, Calif. — Feb. 12, 2007
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase 3 trial in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. Based on this planned interim analysis, the DMC has concluded that the trial met its primary endpoint resulting in superior overall survival (OS) in those patients receiving Nexavar® (sorafenib) tablets versus those patients receiving placebo. The DMC also noted that there was no demonstrated difference in serious adverse event rates between the two treatment arms (Nexavar and placebo). Based on these conclusions, the DMC recommended that the trial be stopped early.

To read the whole story click right here.

0 Comments:

Post a Comment

<< Home